Similarly, a phase 1/2 clinical trial is evaluating the combination of HMA-venetoclax with the TP53-targeted therapy APR-253, which showed high efficacy in combination with azacitidine in TP53-mutated frontline MDS and AML. This evidence concerns the gene TP53 and myelodysplastic syndrome.